|
George Moonsammy, Ph.D. joined Zelos as Vice President of Clinical Development in 2008. Prior to joining Zelos, Dr. Moonsammy was Vice President of Clinical, Regulatory and Medical Affairs at Somerset Pharmaceuticals where he spearheaded the NDA filing and approval of EMSAM, the first transdermal product for the treatment of patients with depression. Dr. Moonsammy also spent 29 years at GlaxoSmithKline (GSK) in increasingly senior roles, most recently as an Associate Director in Clinical R&D and Medical Affairs. During his tenure at GSK, he directed clinical research of pharmaceutical and vaccine products that resulted in the filings of 12 NDAs/sNDAs/BLAs in anti-infective, anti-viral and vaccine products. Dr. Moonsammy received a Ph.D. from Union Institute and University and a Master of Science degree in neurobiology from Washington University School of Medicine. | 